News and Announcements
SUDA Granted Japanese Patent for its Sldenafil-Based Products
- Published March 03, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that the Japan Patent Office has issued SUDA’s first Japanese patent for its sildenafil-based products, SUD-003 and SUD-004. The patent is titled: Oral Spray Formulations and Methods for Administration of Sildenafil. A patent application directed to similar subject matter has also been approved in Russia.
KEY TAKEAWAYS:
- Similar patents have been granted in the USA, Australia, New Zealand and Singapore; patent applications are pending in other jurisdictions.
- These patents provide protection until 2032.
- Administration of sildenafil, being the active pharmaceutical ingredient in SUD-003 and SUD-004, via an oral spray for the treatment of sexual dysfunction induced by Selective Serotonin Reuptake Inhibitor (SSRI) anti-depressants and for the treatment of pulmonary arterial hypertension (PAH).
- The global Erectile Dysfunction (ED) drugs market was valued at over US$ 4.4 billion in 2014. It affects about 150 million men worldwide and about 50% of men aged 40-88 suffer from the disorder.
Mr Stephen J Carter, SUDA’s CEO and Managing Director, commented: “We are delighted to have been issued this patent in Japan and to have had it approved in Russia. It reinforces our proprietary position covering the oral spray delivery of sildenafil for erectile dysfunction and pulmonary arterial hypertension. If we consider all countries where this patent or similar patents have been granted, then we have patent protection for SUD-003 and SUD-004 covering approximately 60% of the world’s healthcare market. We are finalising our new-generation formulation of SUD-003 with enhanced bioavailability and onset of action in preclinical models. In 2017, we anticipate continuing and furthering our discussions with prospective pharmaceutical partners globally who have shown interest in licensing our novel oral spray treatment for erectile dysfunction.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
